bioAffinity Technologies Inc. has announced the issuance of a U.S. patent for their innovative cancer therapy, which utilizes small interfering RNAs (siRNAs) to target and silence specific cell surface receptors, CD320 and LRP2. This approach has shown promise in selectively killing cancer cells across various types, including lung, breast, prostate, brain, and skin cancers, while sparing normal cells. The company also received notification of a patent grant from the China National Intellectual Property Administration, signaling potential global impact for their therapeutic advancements.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。